Precise Cancer Treatment Articles & Analysis
18 news found
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell Lung Cancer (NSCLC) study at the esteemed Johns Hopkins University. ...
A UNIQUE WORKFLOW SOLUTION INTEGRATING A PAN-CANCER NEXT-GENERATION SEQUENCING (NGS) PANEL POWERED BY A BIOINFORMATICS SOFTWARE SUITE FOR CUSTOMIZABLE BIOLOGICAL AND CLINICAL INTERPRETATION ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, TODAY ...
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more cancer patients with access to SEngine’s signature diagnostic test, the PARIS® Test. ...
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. ...
SYNLAB LABORATORIES TO PERFORM ONCODEEP® BIOMARKER TEST TO HELP DOCTORS DECIDE ON THE MOST EFFECTIVE TREATMENT FOR THEIR CANCER PATIENTS ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY A PARTNERSHIP WITH SYNLAB, ...
UNIQUE WORKFLOW SOLUTION INTEGRATING A COMPRENSIVE PAN-CANCER NGS PANEL POWERED BY TWIST BIOSCIENCE AND A BIOINFORMATICS SOFTWARE SUITE ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY THE LAUNCH OF THE ONCODEEP KIT. THE KIT OFFERS A ...
January 26, 2022 – Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and ...
Functional drug screening of patient-derived tumor models is being adopted across cancer types as a tool for oncologists seeking novel treatment options in hard-to-treat cancers. ...
Axumin, a novel amino acid-based radiopharmaceutical, is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. ...
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with BEC GmbH (BEC) to incorporate a customized, robotic patient positioning system as part of its Alphabeam™ Neutron System for the high-precision radiation treatment of tumors. During ...
SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine announces dramatic results for a 52-year-old patient with terminal ovarian cancer who received the PARIS® Test in early summer 2020. ...
Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniature patient- derived tumors that capture the original heterogeneity and microenvironment for therapeutic profiling The company’s platform can deliver personalized precision treatment strategies for patients and accelerate drug discovery and development for ...
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a ...
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session ...
Dr. Chorom Pak, President and CEO, LynxBio was a finalist in the John G. Watson Quick Pitch Competition presented by the Tech Coast Angels and the San Diego Venture Group. She talks about using an advanced approach to diagnosing cancer by using a standard-of-care biopsy to create a living model of a patient's cancer, including the patient's own microenvironment, to rapidly identify effective ...
"It is of utmost importance for Precision to support the promotion of ovarian cancer awareness," says Sean McDonald, CEO of Precision. ...